Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int J Mol Sci ; 24(2)2023 Jan 11.
Artigo em Inglês | MEDLINE | ID: mdl-36674961

RESUMO

Opioid drugs have analgesic properties used to treat chronic and post-surgical pain due to descending pain modulation. The use of opioids is often associated with adverse effects or clinical issues. This study aimed to evaluate the toxicity of opioids by exposing the neuroblastoma cell line (SH-SY5Y) to 0, 1, 10, and 100 µM oxycodone and naloxone for 24 h. Analyses were carried out to evaluate cell cytotoxicity, identification of cell death, DNA damage, superoxide dismutase (SOD), glutathione S-transferase (GST), and acetylcholinesterase (AChE) activities, in addition to molecular docking. Oxycodone and naloxone exposure did not alter the SH-SY5Y cell viability. The exposure to 100 µM oxycodone and naloxone significantly increased the cells' DNA damage score compared to the control group. Naloxone exposure significantly inhibited AChE, GST, and SOD activities, while oxycodone did not alter these enzymes' activities. Molecular docking showed that naloxone and oxycodone interact with different amino acids in the studied enzymes, which may explain the differences in enzymatic inhibition. Naloxone altered the antioxidant defenses of SH-SY5Y cells, which may have caused DNA damage 24 h after the exposure. On the other hand, more studies are necessary to explain how oxycodone causes DNA damage.


Assuntos
Neuroblastoma , Oxicodona , Humanos , Oxicodona/efeitos adversos , Naloxona/farmacologia , Acetilcolinesterase , Simulação de Acoplamento Molecular , Constipação Intestinal/tratamento farmacológico , Neuroblastoma/tratamento farmacológico , Analgésicos Opioides/efeitos adversos , Dor Pós-Operatória/tratamento farmacológico , Linhagem Celular , Superóxido Dismutase , Preparações de Ação Retardada/uso terapêutico , Combinação de Medicamentos
2.
Molecules ; 26(11)2021 05 28.
Artigo em Inglês | MEDLINE | ID: mdl-34071603

RESUMO

Opioids are the most effective analgesics, with most clinically available opioids being agonists to the µ-opioid receptor (MOR). The MOR is also responsible for their unwanted effects, including reward and opioid misuse leading to the current public health crisis. The imperative need for safer, non-addictive pain therapies drives the search for novel leads and new treatment strategies. In this study, the recently discovered MOR/nociceptin (NOP) receptor peptide hybrid KGNOP1 (H-Dmt-D-Arg-Aba-ß-Ala-Arg-Tyr-Tyr-Arg-Ile-Lys-NH2) was evaluated following subcutaneous administration in mouse models of acute (formalin test) and chronic inflammatory pain (Complete Freund's adjuvant-induced paw hyperalgesia), liabilities of spontaneous locomotion, conditioned place preference, and the withdrawal syndrome. KGNOP1 demonstrated dose-dependent antinociceptive effects in the formalin test, and efficacy in attenuating thermal hyperalgesia with prolonged duration of action. Antinociceptive effects of KGNOP1 were reversed by naltrexone and SB-612111, indicating the involvement of both MOR and NOP receptor agonism. In comparison with morphine, KGNOP1 was more potent and effective in mouse models of inflammatory pain. Unlike morphine, KGNOP1 displayed reduced detrimental liabilities, as no locomotor impairment nor rewarding and withdrawal effects were observed. Docking of KGNOP1 to the MOR and NOP receptors and subsequent 3D interaction pattern analyses provided valuable insights into its binding mode. The mixed MOR/NOP receptor peptide KGNOP1 holds promise in the effort to develop new analgesics for the treatment of various pain states with fewer MOR-mediated side effects, particularly abuse and dependence liabilities.


Assuntos
Oligopeptídeos/genética , Peptídeos Opioides/química , Receptores Opioides mu/metabolismo , Dor Aguda/tratamento farmacológico , Analgésicos , Animais , Comportamento Animal , Células CHO , Cricetinae , Cricetulus , Cicloeptanos/farmacologia , Humanos , Hiperalgesia/tratamento farmacológico , Técnicas In Vitro , Inflamação/tratamento farmacológico , Masculino , Camundongos , Modelos Moleculares , Simulação de Acoplamento Molecular , Morfina/química , Morfina/farmacologia , Movimento/efeitos dos fármacos , Naloxona/farmacologia , Naltrexona/farmacologia , Manejo da Dor , Piperidinas/farmacologia , Nociceptina
3.
Behav Pharmacol ; 31(2&3): 186-195, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-30741729

RESUMO

The Toll-like receptor 4 (TLR4) antagonists, (+)-naloxone and (+)-naltrexone, have been reported to decrease self-administration of opioids in rats and to reduce other preclinical indicators of abuse potential. However, under the self-administration conditions studied, the effects of TLR4 antagonists were not reinforcer selective, questioning the involvement of those receptors and their mediated inflammatory response specifically in opioid abuse. The objectives of the current study were to further characterize the reinforcer specificity of TLR4 antagonism in opioid self-administration and to explore its effects in a preclinical model of craving/relapse. The TLR4 antagonist (+)-naltrexone decreased responding in rats trained to self-administer the µ-opioid receptor agonist remifentanil, but with a potency that was not significantly different from that observed in another group of subjects in which responding was maintained by food reinforcement. Responding reinstated by heroin injection was decreased by (+)-naltrexone; however, a similar reduction was not reproduced with the administration of another TLR4 antagonist, lipopolysaccharide from Rhodobacter sphaeroides, administered into the NAcc shell. Thus, TLR4 antagonists lacked reinforcer selectivity in reducing opioid self-administration and were not uniformly effective in a model of craving/relapse, suggesting limitations on the development of (+)-naltrexone or TLR4 antagonists as treatments for opioid abuse.


Assuntos
Naltrexona/farmacologia , Transtornos Relacionados ao Uso de Opioides/fisiopatologia , Receptor 4 Toll-Like/metabolismo , Analgésicos Opioides/metabolismo , Analgésicos Opioides/farmacologia , Animais , Condicionamento Operante/efeitos dos fármacos , Heroína/administração & dosagem , Masculino , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Ratos , Ratos Sprague-Dawley , Reforço Psicológico , Autoadministração , Receptor 4 Toll-Like/antagonistas & inibidores , Receptor 4 Toll-Like/fisiologia
4.
Curr Pharm Teach Learn ; 10(6): 717-722, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-30025771

RESUMO

BACKGROUND AND PURPOSE: Develop a naloxone training activity and assess the activity's impact on increasing student pharmacist knowledge and confidence to counsel about management of opioid overdose and naloxone administration. EDUCATIONAL ACTIVITY AND SETTING: First-year student pharmacists participated in a naloxone training activity in an abilities laboratory course. The students completed pre-lab questions, received a brief lecture about responding to an opioid overdose, and then practiced counseling and administering intranasal and intramuscular naloxone using training kits. An Objective Structured Clinical Examination (OSCE) was conducted to assess students' ability to counsel on intranasal naloxone use in response to opioid overdose. Students completed self-assessments about their confidence in counseling patients about management of opioid overdose and naloxone administration following the OSCE and at course end. FINDINGS: 158 students participated and the average OSCE score was 82%. In the post-encounter self-assessment, 93% of students agreed or completely agreed that the OSCE improved their confidence in counseling about management of an opioid overdose and intranasal naloxone administration. Fifty-nine students completed the end-of-course survey and >90% of respondents reported they were somewhat or very confident in their ability to administer intranasal or intramuscular naloxone, recognize the opioid overdose symptoms, and counsel about intranasal naloxone use. Confidence in counseling about use of intramuscular naloxone was slightly lower. SUMMARY: Further study of training programs to increase future healthcare professionals' ability to respond to opioid overdoses is warranted. Incorporation of a short training activity can increase student pharmacists' knowledge and confidence in counseling patients about opioid overdose and naloxone administration.


Assuntos
Naloxona/uso terapêutico , Estudantes de Farmácia/psicologia , Ensino/normas , Administração Intranasal , Analgésicos Opioides/efeitos adversos , Overdose de Drogas/tratamento farmacológico , Educação em Farmácia/métodos , Humanos , Naloxona/efeitos adversos , Naloxona/farmacologia , Antagonistas de Entorpecentes/efeitos adversos , Antagonistas de Entorpecentes/farmacologia , Antagonistas de Entorpecentes/uso terapêutico , Avaliação de Programas e Projetos de Saúde/métodos , Estudantes de Farmácia/estatística & dados numéricos , Inquéritos e Questionários
5.
Physiol Behav ; 179: 442-450, 2017 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-28716608

RESUMO

Eating disorders are associated with impaired decision-making and dysfunctional reward-related neurochemistry. The present study examined the potential contributions of dopamine and opioid signaling to these processes using two different decision-making tasks. In one task, Long Evans Rats chose between working for a preferred food (high-carbohydrate banana-flavored sucrose pellets) by lever pressing on a progressive-ratio schedule of reinforcement vs. obtaining less preferred laboratory chow that was concurrently available. In a second (effort-free) task, rats chose between the same two reinforcers when they were both available freely. Rats were trained in these tasks before receiving haloperidol (0.00, 0.05, 0.10mg/kg, intraperitoneally (i.p.)) or naloxone (0.0, 1.5, 3.0mg/kg, i.p.). In the first task, haloperidol decreased breakpoint, lever presses, number of reinforcers earned, and increased chow intake, whereas naloxone decreased breakpoint and number of reinforcers earned but had no effect on chow consumption. In the effort-free task, haloperidol reduced intakes of both foods without affecting preference, whereas naloxone selectively reduced the consumption of banana-pellets. The present findings support converging evidence suggesting that DA signaling affects processes more closely related to appetitive motivation, leaving other components of motivation unchanged. By contrast, opioid signaling appears to mediate aspects of hedonic feeding by selectively altering intakes of highly palatable foods. For preferred foods, both appetitive and consummatory aspects of food intake were altered by opioid receptor antagonism. Our findings argue against a general suppression of appetite by either compound, as appetite manipulations have been shown to unselectively alter intakes of both types of food regardless of the task employed.


Assuntos
Tomada de Decisões/fisiologia , Dopamina/metabolismo , Comportamento Alimentar/fisiologia , Motivação/fisiologia , Receptores Opioides/metabolismo , Animais , Apetite/efeitos dos fármacos , Apetite/fisiologia , Tomada de Decisões/efeitos dos fármacos , Antagonistas de Dopamina/farmacologia , Relação Dose-Resposta a Droga , Ingestão de Alimentos/efeitos dos fármacos , Ingestão de Alimentos/fisiologia , Comportamento Alimentar/efeitos dos fármacos , Transtornos da Alimentação e da Ingestão de Alimentos/metabolismo , Haloperidol/farmacologia , Masculino , Motivação/efeitos dos fármacos , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Ratos Long-Evans , Receptores Dopaminérgicos/metabolismo , Reforço Psicológico , Percepção Gustatória/efeitos dos fármacos , Percepção Gustatória/fisiologia
6.
J Pharmacol Exp Ther ; 340(2): 386-92, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22062352

RESUMO

Chronic treatment of pain with opiate drugs can lead to analgesic tolerance and drug dependence. Although all opiate drugs can promote tolerance and dependence in practice, the severity of those unwanted side effects differs depending on the drug used. Although each opiate drug has its own unique set of pharmacological profiles, methadone is the only clinically used opioid drug that produces substantial receptor endocytosis at analgesic doses. Here, we examined whether moderate doses of methadone carry any benefits over chronic use of equianalgesic morphine, the prototypical opioid. Our data show that chronic administration of methadone produces significantly less analgesic tolerance than morphine. Furthermore, we found significantly reduced precipitated withdrawal symptoms after chronic methadone treatment than after chronic morphine treatment. Finally, using a novel animal model with a degrading µ-opioid receptor we showed that, although endocytosis seems to protect against tolerance development, endocytosis followed by receptor degradation produces a rapid onset of analgesic tolerance to methadone. Together, these data indicated that opioid drugs that promote receptor endocytosis and recycling, such as methadone, may be a better choice for chronic pain treatment than morphine and its derivatives that do not.


Assuntos
Metadona/farmacologia , Metadona/uso terapêutico , Morfina/farmacologia , Morfina/uso terapêutico , Dor/prevenção & controle , Analgésicos Opioides , Animais , Área Sob a Curva , Relação Dose-Resposta a Droga , Tolerância a Medicamentos/fisiologia , Endocitose/fisiologia , Técnicas de Introdução de Genes , Metadona/administração & dosagem , Metadona/economia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Morfina/administração & dosagem , Morfina/economia , Mutação/fisiologia , Naloxona/farmacologia , Medição da Dor/métodos , Limiar da Dor/efeitos dos fármacos , Receptores Opioides mu/genética , Receptores Opioides mu/metabolismo , Síndrome de Abstinência a Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/diagnóstico
7.
Psychopharmacology (Berl) ; 203(2): 421-9, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18594795

RESUMO

RATIONALE: The characterization of the discriminative stimulus properties of naloxone has focused primarily on its actions at the mu opioid receptor, although naloxone also displays an affinity for delta and kappa receptor subtypes. OBJECTIVES: The present study extends this characterization of the naloxone cue by investigating if relatively specific antagonists for the mu (naltrexone: 0.10-0.56 mg/kg), delta (naltrindole: 1-18 mg/kg), and kappa (MR2266: 1.8-10 mg/kg) opioid receptor subtypes will substitute for naloxone in animals trained to discriminate naloxone from its vehicle. The temporal nature of the naloxone cue was examined by varying pretreatment time points (15, 30, 45, 60 min). Finally, various doses of naltrexone methobromide (1-18 mg/kg) were assessed to determine peripheral mediation of the cue. MATERIALS AND METHODS: Female Long-Evans rats (N = 30) received an injection of naloxone (1 mg/kg; i.p.) 15 min prior to a pairing of saccharin (20-min access) and the emetic LiCl (1.8 mEq; i.p.; n = 16, group NL) or vehicle (n = 14, group NW); on other days, they were injected with saline prior to saccharin alone. Substitution tests with compounds with various receptor affinities and selective CNS and PNS actions were then assessed. RESULTS: Only naloxone and naltrexone produced dose-dependent decreases in saccharin consumption. Naloxone administered at 15 and 30 min before saccharin produced decreases in consumption similar to that displayed on training days. Naltrexone methobromide substituted only at the highest dose tested (18 mg/kg). CONCLUSIONS: Naloxone's stimulus effects appear to be mediated centrally via activity at the mu opioid receptor.


Assuntos
Aprendizagem por Discriminação/efeitos dos fármacos , Discriminação Psicológica/efeitos dos fármacos , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Paladar/efeitos dos fármacos , Animais , Relação Dose-Resposta a Droga , Ratos , Ratos Long-Evans , Receptores Opioides delta/antagonistas & inibidores , Receptores Opioides kappa/antagonistas & inibidores , Receptores Opioides mu/antagonistas & inibidores , Sacarina/administração & dosagem
8.
Neurosci Lett ; 447(2-3): 175-8, 2008 Dec 12.
Artigo em Inglês | MEDLINE | ID: mdl-18926882

RESUMO

We present simple method to assess dental pain in the awake rat. Using a sensitive strain gauge we examined changes in bite strength and bite pattern in rats following dental injury. Rats with dental injury displayed a significant reduction in mean peak bite strength and an altered bite cluster pattern. Both changes in the dental injury rats were reversed by an analgesic dose of morphine, and this could be reversed with naloxone. These changes were not observed in naive control animals. This simple method significantly improves our ability to evaluate dental pain syndromes.


Assuntos
Força de Mordida , Medição da Dor/métodos , Dor/fisiopatologia , Analgésicos Opioides/farmacologia , Análise de Variância , Animais , Polpa Dentária/efeitos dos fármacos , Polpa Dentária/fisiologia , Análise do Estresse Dentário , Masculino , Morfina/farmacologia , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Dor/diagnóstico , Medição da Dor/instrumentação , Distribuição Aleatória , Ratos , Ratos Long-Evans , Fatores de Tempo
9.
Exp Clin Psychopharmacol ; 14(2): 109-20, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16756415

RESUMO

The subjective, behavioral, and physiologic effects of racemic tramadol, an analgesic with low abuse liability and dual mu-opioid agonist and monoamine reuptake actions, were evaluated in 2 clinical pharmacology studies in dependent opioid abusers. In the withdrawal precipitation study, participants (N = 8) were maintained on methadone 60 mg/day orally and challenged with intramuscular tramadol, hydromorphone, naloxone, and placebo 20 hr after methadone administration. In the withdrawal suppression study, participants (N = 6) were maintained on hydromorphone given orally 10 mg 4 times daily, and spontaneous opioid withdrawal was produced by withholding doses for 23 hr. During the experimentally induced withdrawal, oral tramadol, hydromorphone, naltrexone, and placebo were given. In both studies a comprehensive panel of participant-rated, observer-rated, and physiologic measures were collected. In both studies, naloxone and naltrexone significantly increased measures of opioid withdrawal, whereas tramadol showed no discernible antagonist effects. In contrast, tramadol's pattern of effects was more similar to that of hydromorphone and suggestive of mild opioid-agonist effects (withdrawal suppression), though not to a statistically significant degree.


Assuntos
Analgésicos Opioides/farmacologia , Antagonistas de Entorpecentes/farmacologia , Entorpecentes/farmacologia , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Tramadol/farmacologia , Adulto , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hidromorfona/farmacologia , Pessoa de Meia-Idade , Naloxona/farmacologia
10.
World J Gastroenterol ; 12(17): 2781-4, 2006 May 07.
Artigo em Inglês | MEDLINE | ID: mdl-16718770

RESUMO

AIM: To establish a visceral pain model via colorectal distension (CRD) and to evaluate the efficiency of behavioral responses of CRD by measuring the score of abdominal withdrawal reflex (AWR) in rats. METHODS: Thirty-eight male SD rats weighing 180-240 g were used to establish the visceral pain model. The rat was inserted intra-anally with a 7 cm long flexible latex balloon under ether anesthesia, and colorectal distensions by inflating the balloon with air were made 30 min after recovering from the anesthesia. Five AWR scores (AWR0 to AWR4) were used to assess the intensity of noxious visceral stimuli. It was regarded as the threshold of the minimal pressure (kPa). For abdominal flatting was induced by colorectal distension. RESULTS: A vigorous AWR to distension of the descending colon and rectum was found in 100% of the awake rats tested. The higher the pressure of distension, the higher the score of AWR. The distension pressures of 0, 2.00, 3.33, 5.33 and 8.00 kPa produced different AWR scores (P<0.05). The pain threshold of AWR was constant for up to 80 min after the initial windup (first 1-3 distensions), the mean threshold was 3.69+/-0.35 kPa. Systemic administration of morphine sulfate elevated the threshold of visceral pain in a dose-dependent and naloxone reversible manner. CONCLUSION: Scoring the AWR during colorectal distensions can assess the intensity of noxious visceral stimulus. Flatting of abdomen (AWR 3) to CRD as the visceral pain threshold is clear, constant and reliable. This pain model and its behavioral assessment are good for research on visceral pain and analgesics.


Assuntos
Dor Abdominal/fisiopatologia , Colo/fisiopatologia , Modelos Animais de Doenças , Reto/fisiopatologia , Reflexo/fisiologia , Vísceras/fisiopatologia , Dor Abdominal/tratamento farmacológico , Dor Abdominal/etiologia , Analgésicos/uso terapêutico , Animais , Comportamento Animal/fisiologia , Cateterismo/efeitos adversos , Colo/patologia , Dilatação Patológica/complicações , Dilatação Patológica/fisiopatologia , Masculino , Morfina/antagonistas & inibidores , Morfina/uso terapêutico , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Limiar da Dor , Ratos , Ratos Sprague-Dawley , Reto/patologia , Reprodutibilidade dos Testes , Fatores de Tempo , Vísceras/patologia
11.
Sci Pract Perspect ; 2(2): 4-20, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18552728

RESUMO

Buprenorphine is a new and attractive medication option for many opioid-addicted adults and their physicians. Before initiating buprenorphine treatment, providers must be aware of such critical factors as how the medication works, its efficacy and safety profile, how it is used in opioid withdrawal as well as maintenance treatment, and how patients can best be selected, educated about buprenorphine, and monitored throughout treatment. This article reviews these important issues as well as requirements for physician and staff training and needs for additional research on this unique medication.


Assuntos
Buprenorfina/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Buprenorfina/efeitos adversos , Buprenorfina/farmacologia , Ensaios Clínicos como Assunto , Relação Dose-Resposta a Droga , Interações Medicamentosas , Educação Continuada , Acessibilidade aos Serviços de Saúde/economia , Humanos , Metadona/farmacologia , Metadona/uso terapêutico , Naloxona/farmacologia , Naloxona/uso terapêutico , Antagonistas de Entorpecentes/efeitos adversos , Antagonistas de Entorpecentes/farmacologia , Entorpecentes/farmacologia , Entorpecentes/uso terapêutico , Transtornos Relacionados ao Uso de Opioides/terapia , Educação de Pacientes como Assunto , Seleção de Pacientes
12.
Pharmacol Biochem Behav ; 70(1): 149-56, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11566152

RESUMO

The present study compared male and female mice for frequency of naloxone-precipitated jumping and naloxone ED(50) values, two common indices of physical dependence, following acute and chronic morphine administration. Both sexes displayed a positive dose-response relationship between acute morphine and naloxone doses and jumping frequency. There was a significant main effect of sex, with mean jumping frequencies greater in males. The naloxone ED(50) estimate was also fourfold lower in males, indicating greater withdrawal sensitivity than females. Jumping frequencies were similar in male and female saline-treated control mice, discounting initial sex differences as a significant factor in the unequal magnitude and sensitivity in acute morphine dependence between sexes. In contrast, males and females displayed similar mean withdrawal jumping frequencies and naloxone ED(50) values after 3 days of morphine injections. Sex difference in withdrawal jumping was also not observed when morphine treatment was increased to 7 days via daily injection or continuous subcutaneous infusion. The present study demonstrates the development of greater physical dependence in male relative to female mice following acute but not chronic morphine administration.


Assuntos
Dependência de Morfina , Morfina/farmacologia , Entorpecentes/farmacologia , Animais , Relação Dose-Resposta a Droga , Feminino , Masculino , Camundongos , Dependência de Morfina/fisiopatologia , Atividade Motora/efeitos dos fármacos , Atividade Motora/fisiologia , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Fatores Sexuais , Síndrome de Abstinência a Substâncias/fisiopatologia
13.
Pharmacol Biochem Behav ; 66(4): 851-6, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10973525

RESUMO

Morphine is an effective training drug in drug discrimination procedures. In subsequent generalization tests in which other opioids are administered, mu opioid agonists selectively substitute for the training drug. Given the relative selectivity of morphine for the mu receptor, such substitution patterns suggest that the mu opioid receptor is mediating the discriminative control of this compound. The present study assessed this selective mediation by examining the ability of the delta opioid agonist SNC80 to substitute for (and the delta opioid antagonist naltrindole to antagonize) morphine stimulus effects in rats trained to discriminate morphine from its vehicle in the conditioned taste aversion baseline of drug discrimination learning. Although morphine and methadone produced dose-related substitution for morphine (10 mg/kg), there was no evidence of substitution for morphine by SNC80 at any dose tested. Further, although naloxone (3.2 mg/kg) completely blocked the discriminative effects of morphine, naltrindole (3.2-10 mg/kg) did not significantly affect the morphine stimulus. These data suggest that the discriminative control established to morphine is mediated by its activity at the mu, but not the delta, receptor.


Assuntos
Discriminação Psicológica/efeitos dos fármacos , Morfina/farmacologia , Entorpecentes/farmacologia , Receptores Opioides delta/efeitos dos fármacos , Receptores Opioides mu/efeitos dos fármacos , Animais , Benzamidas/farmacologia , Aprendizagem por Discriminação/efeitos dos fármacos , Relação Dose-Resposta a Droga , Feminino , Generalização da Resposta/efeitos dos fármacos , Metadona/farmacologia , Naloxona/farmacologia , Naltrexona/análogos & derivados , Naltrexona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Piperazinas/farmacologia , Ratos , Ratos Long-Evans , Receptores Opioides delta/antagonistas & inibidores
14.
J Clin Endocrinol Metab ; 81(11): 3883-91, 1996 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8923833

RESUMO

Corticosteroids inhibit ACTH secretion through diverse cellular mechanisms, including direct pituitary and indirect suprapituitary effects. Although exogenous CRH provides a useful assessment of corticotroph function, the suprapituitary component of ACTH regulation has been difficult to assess in humans. Naloxone (NAL) has been reported to stimulate ACTH secretion indirectly through the release of endogenous hypothalamic CRH, suggesting its potential application in the examination of suprapituitary regulation of ACTH secretory dynamics. We sought to examine the inhibitory effects of corticosteroids on kinetic parameters of ACTH secretion, assessed by a deconvolution method, in healthy human subjects. We also sought to directly compare the ACTH responses to serial administration of human CRH and NAL as well as spontaneously occurring ACTH pulses to distinguish pituitary and suprapituitary components of hypothalamic-pituitary-adrenal regulation. Normal healthy subjects (n = 11) received hCRH (0.4 microgram/kg) at 1800 h and then NAL (65 micrograms/kg) at 1930 h, respectively, on 3 separate study days: placebo pretreatment plus CRH/NAL stimulation, metyrapone (MET) pretreatment plus CRH/NAL, or MET alone. Plasma ACTH and serum cortisol were assessed at frequent (every 10 min) intervals during CRH/NAL or placebo infusions (1800-2100 h) on all 3 study days, and deconvolution analysis was performed to determine kinetic parameters of endogenous and stimulated ACTH secretion. Suppression of endogenous cortisol secretion with MET significantly increased both continuous (basal secretion rate) and pulsatile CRH- and NAL-stimulated ACTH bursts (P < 0.05). The increase in total ACTH secreted per burst was related to two distinct effects of cortisol regulating the amplitude (maximum secretion rate) and half-duration (P < 0.05) of secretory bursts. The ACTH responses to CRH and NAL for individual subjects were significantly and positively correlated in both placebo pretreatment plus CRH/NAL stimulation and MET pretreatment plus CRH/NAL studies (P < 0.01). MET administration disproportionately increased the ACTH response to NAL, producing a significant increase (P < 0.01) in the slope of the regression relating ACTH responses to CRH and NAL. The following conclusions were made: 1) endogenous cortisol secretion, even at levels associated with relatively low serum cortisol concentrations, exerts a significant negative feedback effect on both continuous and pulsatile ACTH secretion; 2) cortisol inhibits pulsatile ACTH secretion through distinct regulatory mechanisms that independently modulate both the mass and the duration of ACTH secretory bursts; 3) the differential sensitivity of the CRH- and NAL-stimulated ACTH responses to MET administration suggests that both pituitary and suprapituitary components of the hypothalmic-pituitary-adrenal axis are sensitive to negative regulation over a rapid or intermediate temporal domain. Endogenous cortisol modulates multiple components of dynamical ACTH secretion through composite effects that appear to be mediated through structurally and functionally distinct regulatory domains.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Hidrocortisona/fisiologia , Hormônio Adrenocorticotrópico/sangue , Adulto , Hormônio Liberador da Corticotropina/farmacologia , Retroalimentação/fisiologia , Feminino , Humanos , Hidrocortisona/sangue , Hidrocortisona/metabolismo , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Sistema Hipotálamo-Hipofisário/fisiologia , Cinética , Masculino , Metirapona/farmacologia , Naloxona/farmacologia , Adeno-Hipófise/efeitos dos fármacos , Adeno-Hipófise/metabolismo , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Sistema Hipófise-Suprarrenal/fisiologia , Caracteres Sexuais
15.
Artigo em Inglês | MEDLINE | ID: mdl-9568362

RESUMO

The possible involvement of an endogenous opioid system in the regulation of ovarian development in the red swamp crayfish, Procambarus clarkii, was investigated in vivo. Injections of the opioid, methionine (Met) enkephalin, into females significantly slowed ovarian maturation in a dose-dependent manner. In contrast, injection of the general opioid antagonist, naloxone, produced dose-dependent ovarian maturation. Furthermore, the highly selective delta opioid agonist, DADLE, also inhibited ovarian maturation, whereas a highly selective delta receptor antagonist, ICI-174,864, stimulated ovarian maturation. In view of these results and the fact that Met-enkephalin is a relatively selective delta receptor agonist, we hypothesize that in the crayfish the inhibitory effect of Met-enkephalin involves this type of binding site. Furthermore, it is hypothesized that the inhibitory action of these opioids is due to either (a) stimulation of release of the gonad-inhibiting hormone, (b) inhibition of release of the gonad-stimulating hormone or (c) both (a) and (b).


Assuntos
Astacoidea/efeitos dos fármacos , Leucina Encefalina-2-Alanina/farmacologia , Encefalina Leucina/análogos & derivados , Encefalina Metionina/farmacologia , Ovário/crescimento & desenvolvimento , Animais , Astacoidea/crescimento & desenvolvimento , Encefalina Leucina/farmacologia , Feminino , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Receptores Opioides delta/agonistas , Receptores Opioides delta/antagonistas & inibidores
16.
Am J Drug Alcohol Abuse ; 21(1): 47-63, 1995 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-7762544

RESUMO

Naloxone (0.8 mg, s.c.) effects on opiate withdrawal signs and symptoms and regional brain function were assessed in 10 methadone-maintained patients and 10 healthy subjects in a double-blind, placebo-controlled study. Regional brain function was assessed using single photon emission computerized tomography (SPECT) by evaluating the uptake of [99mTc]d,l-hexamethylpropyleneamine oxime (HMPAO) in the brain, a process related to regional cerebral perfusion. Comparisons of patients and healthy subjects after saline infusion suggested that chronic opiate dependence was associated with lower corrected activity ratios (regional count density/whole brain count density) in frontal and parietal cortices and greater activity ratios in the thalamus. Opiate-dependent patients, but not healthy subjects, developed opiate withdrawal signs and symptoms after naloxone administration. Following naloxone administration, patients undergoing opiate withdrawal exhibited lower whole brain count density than healthy subjects. They also had lower activity ratios in frontal and parietal cortices and increased thalamic activity ratios relative to healthy subjects receiving naloxone. Naloxone administration in healthy subjects, but not opiate withdrawal in patients, was associated with decreased right parietal cortex and increased right temporal cortex and left basal ganglia activity ratios. Relative to naloxone effects in healthy subjects, opiate withdrawal was associated with decreased whole brain count density and a reduced right temporal cortex activity ratio. This preliminary study reports an initial evaluation of HMPAO-SPECT imaging for assessing regional alterations in brain function during opiate dependence and withdrawal. While group differences were reported, the small magnitude of regional alterations in patients undergoing opiate withdrawal raised concern that HMPAO-SPECT methods employed were inadequate for assessing human regional brain function during phases of opiate addiction. Other emerging functional brain imaging technologies should be evaluated relative to improved HMPAO-SPECT methods for this purpose.


Assuntos
Encéfalo/diagnóstico por imagem , Naloxona/farmacologia , Transtornos Relacionados ao Uso de Opioides/diagnóstico por imagem , Síndrome de Abstinência a Substâncias/diagnóstico por imagem , Adulto , Análise de Variância , Gânglios da Base/fisiopatologia , Pressão Sanguínea , Córtex Cerebral/fisiopatologia , Método Duplo-Cego , Feminino , Giro do Cíngulo/fisiopatologia , Humanos , Masculino , Metadona/uso terapêutico , Transtornos Relacionados ao Uso de Opioides/reabilitação , Síndrome de Abstinência a Substâncias/complicações , Tálamo/fisiopatologia , Tomografia Computadorizada de Emissão de Fóton Único
17.
Neurosci Lett ; 185(2): 75-8, 1995 Feb 09.
Artigo em Inglês | MEDLINE | ID: mdl-7746508

RESUMO

The in vivo spare receptor population and the relative efficacies of morphine and the endogenous enkephalins to alleviate thermal nociceptive inputs were compared by using the mu irreversible antagonist beta-funaltrexamine (beta-FNA). Twenty-four hours after i.c.v. administration of beta-FNA at increasing concentrations (0.005-2.5 micrograms), parallel rightward shifts of both morphine and RB 101 (mixed enkephalin-degrading-enzyme inhibitor) dose-response curves, were observed, but the concentration of beta-FNA required to reduce the analgesic responses was about 10 times higher for RB 101 (0.1 microgram) than for morphine (0.01 microgram). The preferential involvement of mu receptors in the analgesic responses obtained after beta-FNA pretreatment, was supported by the inability of the delta-selective antagonist naltrindole to block these effects. In conclusion, it seems that to elicit the same antinociceptive responses, enkephalins could occupy a smaller proportion of mu opioid receptors than morphine, suggesting that the endogenous peptides have a higher efficacy.


Assuntos
Encefalinas/farmacologia , Morfina/farmacologia , Animais , Relação Dose-Resposta a Droga , Masculino , Camundongos , Naloxona/farmacologia , Naltrexona/análogos & derivados , Naltrexona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Nociceptores/efeitos dos fármacos , Receptores Opioides mu
18.
Pharmacol Biochem Behav ; 48(3): 635-42, 1994 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-7938116

RESUMO

Using the conditioned taste aversion baseline of drug discrimination learning, animals were trained to discriminate nalorphine from distilled water. In subsequent generalization tests, the mu-opiate agonist morphine substituted for the nalorphine stimulus in a dose-dependent manner, while the kappa-opiate agonist U50,488H and the mu-opiate antagonists naloxone and naltrexone failed to do so. That the mu-agonist morphine substituted for the nalorphine stimulus while a kappa-agonist and mu-antagonists failed to substitute indicate that the discriminative control that was established with nalorphine in the present study was mu-agonist receptor-mediated. The basis for this selective control by the mu-receptor subtype may be related to the relative salience of receptor activity in opiate-naive animals. The present results suggest that discriminative control by compounds with activity at multiple receptor sites is not uniformly mediated by specific activity at all of those sites. The specific site mediating discriminative control appears to be a function of the specific training drug.


Assuntos
Aprendizagem por Discriminação/efeitos dos fármacos , Nalorfina/farmacologia , Receptores Opioides kappa/efeitos dos fármacos , Receptores Opioides mu/efeitos dos fármacos , (trans)-Isômero de 3,4-dicloro-N-metil-N-(2-(1-pirrolidinil)-ciclo-hexil)-benzenoacetamida , Analgésicos/farmacologia , Animais , Diprenorfina/farmacologia , Relação Dose-Resposta a Droga , Feminino , Generalização do Estímulo/efeitos dos fármacos , Naloxona/farmacologia , Naltrexona/farmacologia , Pirrolidinas/farmacologia , Ratos
19.
Eur J Pharmacol ; 253(3): 283-7, 1994 Mar 03.
Artigo em Inglês | MEDLINE | ID: mdl-8200422

RESUMO

We investigated if continuous activation of opioid receptors by their endogenous ligands could lead to the development of physical dependence. Catheters were implanted for chronic i.v. drug administration in rats and connected to an infusion pump. On the fifth day of perfusion, the severity of naloxone (5 mg/kg s.c.)-precipitated withdrawal was evaluated. Large behavioral changes and body weight losses were observed in rats chronically treated with morphine (0.17 mg/120 microliters/h). In contrast, only one withdrawal symptom (tremor) was significant in rats treated with the mixed inhibitor of enkephalin-degrading enzymes, RB 101 (1.20 mg/120 microliters/h). Morphine and RB 101 were perfused at doses which give same analgesic responses 6 h after the start of perfusion. This lack of physical dependence after drastic conditions of administration emphasizes the potential clinical interest of systemically active mixed inhibitors as new analgesics.


Assuntos
Comportamento Animal/efeitos dos fármacos , Dissulfetos/farmacologia , Inibidores Enzimáticos/farmacologia , Fenilalanina/análogos & derivados , Transtornos Relacionados ao Uso de Substâncias , Analgésicos/farmacologia , Animais , Cateterismo Venoso Central , Dissulfetos/administração & dosagem , Inibidores Enzimáticos/administração & dosagem , Injeções Subcutâneas , Masculino , Dependência de Morfina , Naloxona/administração & dosagem , Naloxona/farmacologia , Fenilalanina/administração & dosagem , Fenilalanina/farmacologia , Ratos , Ratos Sprague-Dawley , Síndrome de Abstinência a Substâncias
20.
Pharmacol Biochem Behav ; 46(1): 237-42, 1993 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8255917

RESUMO

Recently, cholecystokinin (CCK) has been reported to antagonize a variety of opiate-induced effects, including nociception, body shaking, thermoregulation, and locomotion. Consistent with these results, a number of CCK antagonists potentiate the opiates in a range of behavioral and physiological assessments. The present study further examined the interaction between CCK and the opiates within the conditioned taste aversion baseline of drug discrimination learning, a design that utilizes the stimulus properties of the drug to control consummatory behavior. Specifically, animals injected with CCK prior to saccharin-LiCl pairings and the CCK vehicle prior to saccharin alone rapidly acquired the CCK-vehicle discrimination, avoiding saccharin consumption following the administration of CCK and consuming the same saccharin solution following the vehicle. Although the stimulus properties of CCK did not generalize to either naloxone or diprenorphine, morphine blocked and naloxone potentiated CCK's stimulus effects. These data are thus consistent with a physiological (rather than a pharmacological) interaction between CCK and the opiates.


Assuntos
Colecistocinina/farmacologia , Discriminação Psicológica/efeitos dos fármacos , Entorpecentes/farmacologia , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Colecistocinina/antagonistas & inibidores , Diprenorfina/farmacologia , Interações Medicamentosas , Feminino , Generalização Psicológica/efeitos dos fármacos , Cloreto de Lítio/farmacologia , Morfina/farmacologia , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA